<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016323</url>
  </required_header>
  <id_info>
    <org_study_id>HR19042-201</org_study_id>
    <nct_id>NCT05016323</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of HR19042 capsules compared to matching&#xD;
      placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, double-blind, multicenter, placebo-controlled, parallel groups, Phase II clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urine protein creatinine ratio (UPCR)</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour proteinuria</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine albumin creatinine ratio (UACR)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in estimated GFR</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in estimated GFR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>HR19042 Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR19042 Capsules</intervention_name>
    <description>HR19042 Capsules</description>
    <arm_group_label>HR19042 Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or male patients ≥18 years old；&#xD;
&#xD;
          2. Biopsy-confirmed primary IgA nephropathy；&#xD;
&#xD;
          3. Urine protein≥0.75 g/24hr or urine protein creatinine ratio (UPCR)≥0.5 g/g；&#xD;
&#xD;
          4. Estimated GFR (using the CKD-EPI2009 formula) ≥30mL/min/1.73 m2；&#xD;
&#xD;
          5. Willing and able to take adequate contraception during the trial;&#xD;
&#xD;
          6. Willing and able to give informed consent and follow the protocols during the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Systemic diseases which could lead to secondary IgA nephropathy；&#xD;
&#xD;
          2. Patients with severe chronic infection or active infection under systemic antibiotic&#xD;
             therapy in previous 14 days；&#xD;
&#xD;
          3. Patients with severe cardiovascular diseases；&#xD;
&#xD;
          4. Patients diagnosed with malignancy within the past 5 years；&#xD;
&#xD;
          5. Patients with liver cirrhosis；&#xD;
&#xD;
          6. Patients received organ transplantation；&#xD;
&#xD;
          7. Patients with uncontrolled Type 1 or 2 diabetes；&#xD;
&#xD;
          8. Positive results in HIV-Ab/TP-Ab/ HBsAg/HCV-Ab tests；&#xD;
&#xD;
          9. Patients treated with any systemic immunosuppressive drugs (excluding corticosteroids)&#xD;
             within the past 12 months before screening；&#xD;
&#xD;
         10. Patients treated with any systemic corticosteroids within the past 3 months before&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Cao, M.D</last_name>
    <phone>+0518-81220121</phone>
    <email>yong.cao@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NanFang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanfan Hou, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

